For example, bevacizumab (targeting vascular endothelial growth factor [VEGF]) has been approved by FDA to be used for the treatment of GBM that is refractory or poorly responsive to other treatments (Diaz et al., 2017). This evidence concerns the gene VEGFA and glioblastoma.